{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T08:39:50Z","timestamp":1773304790210,"version":"3.50.1"},"reference-count":127,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2019,2,11]],"date-time":"2019-02-11T00:00:00Z","timestamp":1549843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JoF"],"abstract":"<jats:p>The purpose of this article is to review and update the strategies for prevention and treatment of invasive aspergillosis (IA) in pediatric patients with leukemia and in patients with hematopoietic stem cell transplantation. The major risk factors associated with IA will be described since their recognition constitutes the first step of prevention. The latter is further analyzed into chemoprophylaxis and non-pharmacologic approaches. Triazoles are the mainstay of anti-fungal prophylaxis while the other measures revolve around reducing exposure to mold spores. Three levels of treatment have been identified: (a) empiric, (b) pre-emptive, and (c) targeted treatment. Empiric is initiated in febrile neutropenic patients and uses mainly caspofungin and liposomal amphotericin B (LAMB). Pre-emptive is a diagnostic driven approach attempting to reduce unnecessary use of anti-fungals. Treatment targeted at proven or probable IA is age-dependent, with voriconazole and LAMB being the cornerstones in &gt;2yrs and &lt;2yrs age groups, respectively.<\/jats:p>","DOI":"10.3390\/jof5010014","type":"journal-article","created":{"date-parts":[[2019,2,12]],"date-time":"2019-02-12T03:18:20Z","timestamp":1549941500000},"page":"14","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Invasive Aspergillosis in Pediatric Leukemia Patients: Prevention and Treatment"],"prefix":"10.3390","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2920-5136","authenticated-orcid":false,"given":"Savvas","family":"Papachristou","sequence":"first","affiliation":[{"name":"Infectious Diseases Unit, 3rd Department of Pediatrics, Faculty of Medicine, Aristotle University School of Health Sciences, Konstantinoupoleos 49, 54642 Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9881-451X","authenticated-orcid":false,"given":"Elias","family":"Iosifidis","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, 3rd Department of Pediatrics, Faculty of Medicine, Aristotle University School of Health Sciences, Konstantinoupoleos 49, 54642 Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0202-364X","authenticated-orcid":false,"given":"Emmanuel","family":"Roilides","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, 3rd Department of Pediatrics, Faculty of Medicine, Aristotle University School of Health Sciences, Konstantinoupoleos 49, 54642 Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2019,2,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.medmal.2015.04.006","article-title":"An update on pediatric invasive aspergillosis","volume":"45","author":"Frange","year":"2015","journal-title":"Med. Mal. Infect."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/01.inf.0000157218.37603.84","article-title":"Pediatric aspergillosis: Disease and treatment differences in children","volume":"24","author":"Steinbach","year":"2005","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_4","first-page":"187","article-title":"Invasive fungal infections in children: Recent advances in diagnosis and treatment","volume":"11","author":"Walsh","year":"1996","journal-title":"Adv. Pediatr. Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/cid\/cir786","article-title":"Invasive aspergillosis in children with acquired immunodeficiencies","volume":"54","author":"Tragiannidis","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e1286-94","DOI":"10.1542\/peds.2007-2117","article-title":"Pediatric invasive aspergillosis: A multicenter retrospective analysis of 139 contemporary cases","volume":"121","author":"Burgos","year":"2008","journal-title":"Pediatrics"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/MPH.0000000000000159","article-title":"Invasive aspergillosis in children with acute leukemia at a resource-limited oncology center","volume":"37","author":"Jain","year":"2015","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e327-40","DOI":"10.1016\/S1470-2045(14)70017-8","article-title":"Fourth European Conference on Infections in Leukaemia (ECIL-4): Guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation","volume":"15","author":"Groll","year":"2014","journal-title":"Lancet. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.ejca.2011.01.021","article-title":"Time for paediatric febrile neutropenia guidelines\u2014children are not little adults","volume":"47","author":"Sung","year":"2011","journal-title":"Eur. J. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1111\/j.1469-0691.2010.03334.x","article-title":"Update on antifungal agents for paediatric patients","volume":"16","author":"Groll","year":"2010","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1097\/INF.0b013e3181b076b1","article-title":"Invasive fungal infections in children","volume":"28","author":"Dornbusch","year":"2009","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1111\/bcp.12025","article-title":"Antifungal agents and therapy for infants and children with invasive fungal infections: A pharmacological perspective","volume":"75","author":"Lestner","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of Aspergillus diseases: Executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"24","author":"Ullmann","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s00431-007-0527-7","article-title":"Fungal infections in primary immunodeficiencies","volume":"166","author":"Antachopoulos","year":"2007","journal-title":"Eur. J. Pediatr."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1086\/514717","article-title":"Invasive pulmonary aspergillosis in a critically ill neonate: Case report and review of invasive aspergillosis during the first 3 months of life","volume":"27","author":"Groll","year":"1998","journal-title":"Clin. Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0163-4453(96)92700-0","article-title":"Trends in the postmortem epidemiology of invasive fungal infections at a university hospital","volume":"33","author":"Groll","year":"1996","journal-title":"J. Infect."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.riam.2009.04.001","article-title":"Aspergillosis in patients treated with monoclonal antibodies","volume":"26","author":"Nedel","year":"2009","journal-title":"Rev. Iberoam. Micol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1086\/651262","article-title":"Invasive fungal infections among organ transplant recipients: Results of the Transplant-Associated Infection Surveillance Network (TRANSNET)","volume":"50","author":"Pappas","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1086\/313445","article-title":"Aspergillosis in children with cancer: A 34-year experience","volume":"29","author":"Abbasi","year":"1999","journal-title":"Clin. Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1046\/j.1439-0507.1999.00496.x","article-title":"Five-year-survey of invasive aspergillosis in a paediatric cancer centre. Epidemiology, management and long-term survival","volume":"42","author":"Groll","year":"1999","journal-title":"Mycoses"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e711-6","DOI":"10.1542\/peds.2005-1161","article-title":"Epidemiology, outcomes, and costs of invasive aspergillosis in immunocompromised children in the United States, 2000","volume":"117","author":"Zaoutis","year":"2006","journal-title":"Pediatrics"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1097\/MPH.0b013e3181acd956","article-title":"Increasing incidence of invasive aspergillosis in pediatric hematology oncology patients over the last decade: A retrospective single centre study","volume":"31","author":"Rubio","year":"2009","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/pbc.21868","article-title":"Invasive fungal infections in pediatric leukemia patients receiving fluconazole prophylaxis","volume":"52","author":"Kaya","year":"2009","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00247-003-0919-4","article-title":"The radiological spectrum of invasive aspergillosis in children: A 10-year review","volume":"33","author":"Thomas","year":"2003","journal-title":"Pediatr. Radiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/pbc.23415","article-title":"Antifungal prophylaxis in pediatric hematology\/oncology: New choices & new data","volume":"59","author":"Dvorak","year":"2012","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"685","DOI":"10.2165\/11599810-000000000-00000","article-title":"Antifungal chemoprophylaxis in children and adolescents with haematological malignancies and following allogeneic haematopoietic stem cell transplantation: Review of the literature and options for clinical practice","volume":"72","author":"Tragiannidis","year":"2012","journal-title":"Drugs"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/jpids\/pix030","article-title":"Risk Factors for Invasive Fungal Disease in Pediatric Cancer and Hematopoietic Stem Cell Transplantation: A Systematic Review","volume":"7","author":"Fisher","year":"2018","journal-title":"J. Pediatric Infect. Dis. Soc."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1399-3062.2008.00304.x","article-title":"Invasive aspergillosis and allogeneic hematopoietic stem cell transplantation in children: A 15-year experience","volume":"10","author":"Crassard","year":"2008","journal-title":"Transpl. Infect. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1200\/JCO.2016.71.7017","article-title":"Guideline for the Management of Fever and Neutropenia in Children With Cancer and Hematopoietic Stem-Cell Transplantation Recipients: 2017 Update","volume":"35","author":"Lehrnbecher","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1086\/651263","article-title":"Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: Overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database","volume":"50","author":"Kontoyiannis","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1439-0507.2009.01691.x","article-title":"The changing face of epidemiology of invasive fungal disease in Europe","volume":"52","year":"2009","journal-title":"Mycoses"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4358","DOI":"10.1182\/blood-2002-05-1496","article-title":"Invasive aspergillosis in allogeneic stem cell transplant recipients: Changes in epidemiology and risk factors","volume":"100","author":"Marr","year":"2002","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMra0808853","article-title":"Aspergillosis","volume":"360","author":"Segal","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.bbmt.2007.08.049","article-title":"Higher risk of cytomegalovirus and aspergillus infections in recipients of T cell-depleted unrelated bone marrow: Analysis of infectious complications in patients treated with T cell depletion versus immunosuppressive therapy to prevent graft-versus-host","volume":"13","author":"Carter","year":"2007","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/1469-0691.12040","article-title":"ESCMID* guideline for the diagnosis and management of Candida diseases 2012: Prevention and management of invasive infections in neonates and children caused by Candida spp.","volume":"18","author":"Hope","year":"2012","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1086\/652761","article-title":"Geoclimatic influences on invasive aspergillosis after hematopoietic stem cell transplantation","volume":"50","author":"Panackal","year":"2010","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"E86","DOI":"10.1086\/342305","article-title":"Cleaning patient shower facilities: A novel approach to reducing patient exposure to aerosolized Aspergillus species and other opportunistic molds","volume":"35","author":"Anaissie","year":"2002","journal-title":"Clin. Infect. Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1086\/338958","article-title":"Pathogenic Aspergillus species recovered from a hospital water system: A 3-year prospective study","volume":"34","author":"Anaissie","year":"2002","journal-title":"Clin. Infect. Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"4101","DOI":"10.1128\/JCM.41.9.4101-4106.2003","article-title":"Molecular epidemiology of Aspergillus fumigatus isolates recovered from water, air, and patients shows two clusters of genetically distinct strains","volume":"41","author":"Warris","year":"2003","journal-title":"J. Clin. Microbiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1046\/j.1439-0507.1999.00518.x","article-title":"Itraconazole trough concentrations in antifungal prophylaxis with six different dosing regimens using hydroxypropyl-beta-cyclodextrin oral solution or coated-pellet capsules","volume":"42","author":"Glasmacher","year":"1999","journal-title":"Mycoses"},{"key":"ref_41","first-page":"213","article-title":"Itraconazole prophylaxis in pediatric cancer patients receiving conventional chemotherapy or autologous stem cell transplants","volume":"15","author":"Simon","year":"2007","journal-title":"Support. Care cancer Off. J. Multinatl. Assoc. Support. Care Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s10096-013-1998-2","article-title":"Comparison of itraconazole, voriconazole, and posaconazole as oral antifungal prophylaxis in pediatric patients following allogeneic hematopoietic stem cell transplantation","volume":"33","author":"Doring","year":"2014","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1399-3046.2006.00643.x","article-title":"Intravenous and oral sequential itraconazole antifungal prophylaxis in paediatric stem cell transplantation recipients: A pilot study for evaluation of safety and efficacy","volume":"11","author":"Grigull","year":"2007","journal-title":"Pediatr. Transplant."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1365-2141.2005.05727.x","article-title":"Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: A meta-analysis of randomised-controlled trials","volume":"131","author":"Vardakas","year":"2005","journal-title":"Br. J. Haematol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1365-2141.2011.08838.x","article-title":"Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation","volume":"155","author":"Marks","year":"2011","journal-title":"Br. J. Haematol."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Gastine, S., Lehrnbecher, T., Muller, C., Farowski, F., Bader, P., Ullmann-Moskovits, J., Cornely, O.A., Groll, A.H., and Hempel, G. (2018). Pharmacokinetic Modeling of Voriconazole To Develop an Alternative Dosing Regimen in Children. Antimicrob. Agents Chemother., 62.","DOI":"10.1128\/AAC.01194-17"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/cid\/cis599","article-title":"The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: A randomized controlled trial","volume":"55","author":"Park","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"4782","DOI":"10.1128\/AAC.01083-10","article-title":"Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients","volume":"55","author":"Troke","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/MPH.0000000000000926","article-title":"Voriconazole Antifungal Prophylaxis in Children With Malignancies: A Nationwide Study","volume":"40","author":"Pana","year":"2018","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Iosifidis, E., Papachristou, S., and Roilides, E. (2018). Advances in the Treatment of Mycoses in Pediatric Patients. J. Fungi (Basel, Switzerland), 4.","DOI":"10.3390\/jof4040115"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00431-012-1758-9","article-title":"Antifungal therapy in children: An update","volume":"172","author":"Cecinati","year":"2013","journal-title":"Eur. J. Pediatr."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s10096-010-1123-8","article-title":"Retrospective survey on the off-label use of posaconazole in pediatric hematology patients","volume":"30","author":"Cesaro","year":"2011","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa061098","article-title":"Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease","volume":"356","author":"Ullmann","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1007\/s00432-017-2369-7","article-title":"Efficacy, safety and feasibility of antifungal prophylaxis with posaconazole tablet in paediatric patients after haematopoietic stem cell transplantation","volume":"143","author":"Doring","year":"2017","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/clpt.2010.64","article-title":"Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: Evaluating the need to adjust doses based on drug concentrations in plasma","volume":"88","author":"Jang","year":"2010","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1111\/j.1469-0691.2011.03483.x","article-title":"Liposomal amphotericin B twice weekly as antifungal prophylaxis in paediatric haematological malignancy patients","volume":"17","author":"Bochennek","year":"2011","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.bbmt.2005.10.010","article-title":"High-dose weekly AmBisome antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: A pharmacokinetic study","volume":"12","author":"Mehta","year":"2006","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1093\/jac\/dkp196","article-title":"Safety, tolerance and outcome of treatment with liposomal amphotericin B in paediatric patients with cancer or undergoing haematopoietic stem cell transplantation","volume":"64","author":"Kolve","year":"2009","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1086\/422312","article-title":"Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation","volume":"39","author":"Ratanatharathorn","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s15010-014-0601-9","article-title":"Safety, tolerability, and feasibility of antifungal prophylaxis with micafungin at 2 mg\/kg daily in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation","volume":"42","author":"Yoshikawa","year":"2014","journal-title":"Infection"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1128\/AAC.50.1.143-147.2006","article-title":"Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies","volume":"50","author":"Mattiuzzi","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Doring, M., Hartmann, U., Erbacher, A., Lang, P., Handgretinger, R., and Muller, I. (2012). Caspofungin as antifungal prophylaxis in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation: A retrospective analysis. BMC Infect. Dis., 12.","DOI":"10.1186\/1471-2334-12-151"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1007\/s12325-017-0534-7","article-title":"Comparison of Efficacy and Safety of Caspofungin Versus Micafungin in Pediatric Allogeneic Stem Cell Transplant Recipients: A Retrospective Analysis","volume":"34","author":"Maximova","year":"2017","journal-title":"Adv. Ther."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1086\/319366","article-title":"Guide to development of practice guidelines","volume":"32","author":"Kish","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.3324\/haematol.2009.020073","article-title":"Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: Results of the VOSIFI study","volume":"95","author":"Cordonnier","year":"2010","journal-title":"Haematologica"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1093\/jac\/dkm521","article-title":"Secondary antifungal prophylaxis in paediatric allogeneic haematopoietic stem cell recipients","volume":"61","author":"Allinson","year":"2008","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.bbmt.2009.06.019","article-title":"Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: A global perspective","volume":"15","author":"Tomblyn","year":"2009","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s11046-009-9247-z","article-title":"Infection control measures to prevent invasive mould diseases in hematopoietic stem cell transplant recipients","volume":"168","author":"Liddell","year":"2009","journal-title":"Mycopathologia"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1365-2141.2012.09156.x","article-title":"A prospective, randomized study of empirical antifungal therapy for the treatment of chemotherapy-induced febrile neutropenia in children","volume":"158","author":"Caselli","year":"2012","journal-title":"Br. J. Haematol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1046\/j.1365-2141.1997.2473063.x","article-title":"A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients","volume":"98","author":"Prentice","year":"1997","journal-title":"Br. J. Haematol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/00043426-200005000-00009","article-title":"Use of amphotericin B colloidal dispersion in children","volume":"22","author":"Sandler","year":"2000","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/INF.0b013e3181da2171","article-title":"A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia","volume":"29","author":"Maertens","year":"2010","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"4536","DOI":"10.1128\/AAC.49.11.4536-4545.2005","article-title":"Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents","volume":"49","author":"Walsh","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJM200201243460403","article-title":"Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever","volume":"346","author":"Walsh","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.4081\/pr.2012.e2","article-title":"Empiric antibiotic therapy in a child with cancer and suspected septicemia","volume":"4","author":"Caselli","year":"2012","journal-title":"Pediatr. Rep."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","article-title":"Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) C","volume":"46","author":"Walsh","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1093\/jpids\/pix054","article-title":"Role of Molecular Biomarkers in the Diagnosis of Invasive Fungal Diseases in Children","volume":"6","author":"Huppler","year":"2017","journal-title":"J. Pediatric Infect. Dis. Soc."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1093\/cid\/ciw592","article-title":"Galactomannan, beta-D-Glucan, and Polymerase Chain Reaction-Based Assays for the Diagnosis of Invasive Fungal Disease in Pediatric Cancer and Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis","volume":"63","author":"Lehrnbecher","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1093\/jac\/dky244","article-title":"Efficacy of pre-emptive versus empirical antifungal therapy in children with cancer and high-risk febrile neutropenia: A randomized clinical trial","volume":"73","author":"Santolaya","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1128\/CMR.00046-13","article-title":"Tissue penetration of antifungal agents","volume":"27","author":"Felton","year":"2014","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1182\/blood-2003-07-2512","article-title":"Cyclophosphamide metabolism is affected by azole antifungals","volume":"103","author":"Marr","year":"2004","journal-title":"Blood"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis","volume":"347","author":"Herbrecht","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1086\/525258","article-title":"Treatment of aspergillosis: Clinical practice guidelines of the Infectious Diseases Society of America","volume":"46","author":"Walsh","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Wattier, R.L., and Ramirez-Avila, L. (2016). Pediatric Invasive Aspergillosis. J. fungi (Basel, Switzerland), 2.","DOI":"10.3390\/jof2020019"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1128\/AAC.48.6.2166-2172.2004","article-title":"Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration","volume":"48","author":"Walsh","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1128\/AAC.05761-11","article-title":"Integrated population pharmacokinetic analysis of voriconazole in children, adolescents, and adults","volume":"56","author":"Friberg","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1093\/jac\/dkw099","article-title":"Utility of voriconazole therapeutic drug monitoring: A meta-analysis","volume":"71","author":"Luong","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1086\/514341","article-title":"Liposomal amphotericin B as initial therapy for invasive mold infection: A randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)","volume":"44","author":"Cornely","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s10096-005-0080-0","article-title":"Adverse effects of antifungal therapies in invasive fungal infections: Review and meta-analysis","volume":"25","author":"Girois","year":"2006","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1086\/380796","article-title":"Guidelines for treatment of candidiasis","volume":"38","author":"Pappas","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1517\/14656560802560005","article-title":"Therapeutic strategies for invasive fungal infections in neonatal and pediatric patients","volume":"9","author":"Filioti","year":"2008","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1128\/AAC.04109-14","article-title":"Systemic antifungal prescribing in neonates and children: Outcomes from the Antibiotic Resistance and Prescribing in European Children (ARPEC) Study","volume":"59","author":"Lestner","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1086\/423381","article-title":"Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy","volume":"39","author":"Maertens","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1542\/peds.2008-1158","article-title":"A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients","volume":"123","author":"Zaoutis","year":"2009","journal-title":"Pediatrics"},{"key":"ref_96","first-page":"305","article-title":"Efficacy and safety of caspofungin in children: Systematic review and meta-analysis","volume":"114","author":"Rosanova","year":"2016","journal-title":"Arch. Argent. Pediatr."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1128\/AAC.49.8.3317-3324.2005","article-title":"Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients","volume":"49","author":"Seibel","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Lee, C.-H., Lin, J.-C., Ho, C.-L., Sun, M., Yen, W.-T., and Lin, C. (2017). Efficacy and safety of micafungin versus extensive azoles in the prevention and treatment of invasive fungal infections for neutropenia patients with hematological malignancies: A meta-analysis of randomized controlled trials. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0180050"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1128\/AAC.42.2.404","article-title":"Repeated-dose pharmacokinetics of an oral solution of itraconazole in infants and children","volume":"42","author":"Ratelle","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1086\/508774","article-title":"Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: An externally controlled trial","volume":"44","author":"Walsh","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1128\/AAC.50.2.632-638.2006","article-title":"Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections","volume":"50","author":"Benjamin","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_102","first-page":"374","article-title":"Anidulafungin in children: Experience in a tertiary care children\u2019s hospital in Argentina","volume":"115","author":"Rosanova","year":"2017","journal-title":"Arch. Argent. Pediatr."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Roilides, E., Carlesse, F., Leister-Tebbe, H., Conte, U., Yan, J.L., Liu, P., Tawadrous, M., Aram, J.A., and Queiroz-Telles, F. (2018). A Prospective, Open-label Study to Assess the Safety, Tolerability, and Efficacy of Anidulafungin in the Treatment of Invasive Candidiasis in Children 2 to <18 Years of Age. Pediatr. Infect. Dis. J.","DOI":"10.1097\/INF.0000000000002237"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1093\/cid\/civ571","article-title":"Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent","volume":"61","author":"Miceli","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): A phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet (London, England)"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"e27281","DOI":"10.1002\/pbc.27281","article-title":"Successful treatment of invasive mucormycosis with isavuconazole in pediatric patients","volume":"65","author":"Barg","year":"2018","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/jpids\/piu074","article-title":"A Prospective, International Cohort Study of Invasive Mold Infections in Children","volume":"4","author":"Wattier","year":"2015","journal-title":"J. Pediatric Infect. Dis. Soc."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Cesaro, S., Giacchino, M., Locatelli, F., Spiller, M., Buldini, B., Castellini, C., Caselli, D., Giraldi, E., Tucci, F., and Tridello, G. (2007). Safety and efficacy of a caspofungin-based combination therapy for treatment of proven or probable aspergillosis in pediatric hematological patients. BMC Infect. Dis., 7.","DOI":"10.1186\/1471-2334-7-28"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7326\/M13-2508","article-title":"Combination antifungal therapy for invasive aspergillosis: A randomized trial","volume":"162","author":"Marr","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.3109\/13693786.2010.499916","article-title":"Aspergillus species intrinsically resistant to antifungal agents","volume":"49","author":"Warris","year":"2011","journal-title":"Med. Mycol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nrmicro1179","article-title":"Evolution of antifungal-drug resistance: Mechanisms and pathogen fitness","volume":"3","author":"Anderson","year":"2005","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/cid\/civ885","article-title":"Azole Resistance in Aspergillus fumigatus: Can We Retain the Clinical Use of Mold-Active Antifungal Azoles?","volume":"62","author":"Verweij","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.drup.2015.08.001","article-title":"International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus","volume":"21\u201322","author":"Verweij","year":"2015","journal-title":"Drug Resist. Updat."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/INF.0b013e3182037879","article-title":"Pulmonary aspergillosis caused by a pan-azole-resistant Aspergillus fumigatus in a 10-year-old boy","volume":"30","author":"Thors","year":"2011","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Estcourt, L.J., Stanworth, S., Doree, C., Blanco, P., Hopewell, S., Trivella, M., and Massey, E. (2015). Granulocyte transfusions for preventing infections in people with neutropenia or neutrophil dysfunction. Cochrane database Syst. Rev., CD005341.","DOI":"10.1002\/14651858.CD005341.pub3"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.1182\/blood-2005-05-1775","article-title":"Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation","volume":"106","author":"Perruccio","year":"2005","journal-title":"Blood"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.critrevonc.2015.10.005","article-title":"Adoptive transfer of Aspergillus-specific T cells as a novel anti-fungal therapy for hematopoietic stem cell transplant recipients: Progress and challenges","volume":"98","author":"Papadopoulou","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1086\/318483","article-title":"Aspergillosis case-fatality rate: Systematic review of the literature","volume":"32","author":"Lin","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1086\/509917","article-title":"Imaging findings in acute invasive pulmonary aspergillosis: Clinical significance of the halo sign","volume":"44","author":"Greene","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.ijid.2007.01.013","article-title":"Central nervous system aspergillosis in children: A systematic review of reported cases","volume":"11","author":"Dotis","year":"2007","journal-title":"Int. J. Infect. Dis."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1179\/1973947815Y.0000000009","article-title":"Need of voriconazole high dosages, with documented cerebrospinal fluid penetration, for treatment of cerebral aspergillosis in a 6-month-old leukaemic girl","volume":"29","author":"Palmisani","year":"2017","journal-title":"J. Chemother."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1056\/NEJMra1216008","article-title":"Mold infections of the central nervous system","volume":"371","author":"McCarthy","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1093\/infdis\/155.4.766","article-title":"Pharmacokinetics of amphotericin B in infants and children","volume":"155","author":"Starke","year":"1987","journal-title":"J. Infect. Dis."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1182\/blood-2005-02-0733","article-title":"Improved outcome in central nervous system aspergillosis, using voriconazole treatment","volume":"106","author":"Schwartz","year":"2005","journal-title":"Blood"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1086\/315643","article-title":"Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system","volume":"182","author":"Groll","year":"2000","journal-title":"J. Infect. Dis."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1128\/AAC.01540-12","article-title":"Highly variable plasma concentrations of voriconazole in pediatric hematopoietic stem cell transplantation patients","volume":"57","author":"Bartelink","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1053\/srin.2001.29298","article-title":"Intrathecal amphotericin in the management of coccidioidal meningitis","volume":"16","author":"Stevens","year":"2001","journal-title":"Semin. Respir. Infect."}],"container-title":["Journal of Fungi"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2309-608X\/5\/1\/14\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:31:02Z","timestamp":1760185862000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2309-608X\/5\/1\/14"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,11]]},"references-count":127,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,3]]}},"alternative-id":["jof5010014"],"URL":"https:\/\/doi.org\/10.3390\/jof5010014","relation":{},"ISSN":["2309-608X"],"issn-type":[{"value":"2309-608X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,11]]}}}